Determination of Plasma ET-1 by RIA - Risks and Limitations

S. M. Baumgartner-Parzer; P. Nowotny; O. Wagner; W. Waldhäusl

doi:10.1055/s-2007-978948

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000025.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Horm Metab Res 1998; 30(10): 633-635
DOI: 10.1055/s-2007-978948

Originals Clinical

Determination of Plasma ET-1 by RIA - Risks and Limitations

S. M. Baumgartner-Parzer¹ , P. Nowotny¹ , O. Wagner² , W. Waldhäusl¹

¹Department of Internal Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Austria
²Institute of Clinical Chemistry and Pathobiochemistry, University of Leipzig, Germany

Further Information

Publication History

1998

1998

Publication Date:
20 April 2007 (online)

Also available at

PDF Download Permissions and Reprints

Plasma concentrations of the vasoconstrictor peptide endothelin-1 (ET-1) were determined in nonobese healthy subjects as well as in unspecified patients using three different commercially available radioimmunoassays (RIAs) and the respective recommended prepurification procedures. Depending on the antibody and extraction procedure applied different ET-1 concentrations were measured in identical plasma samples. Thus, this study clearly documents that ET-1 concentrations measured in plasma samples represent apparent concentrations which have to be interpreted with caution.

Key words

Endothelin-1 - Plasma Concentration - Radioimmunoassay - Quality Control